Ofloxacin Tablets Rx
Generic Name and Formulations:
Ofloxacin 200mg, 300mg, 400mg; tabs.
Various generic manufacturers
Indications for Ofloxacin Tablets:
Susceptible infections including acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, acute pelvic inflammatory disease (PID), acute, uncomplicated cervical and urethral gonorrhea, urethritis, cervicitis, uncomplicated cystitis, uncomplicated skin and skin structure, complicated UTIs, prostatitis.
≥18yrs: Take with full glass water. Bronchitis, pneumonia, uncomplicated skin and skin structure: 400mg every 12 hours for 10 days. Urethritis, cervicitis: 300mg every 12 hours for 7 days. Gonorrhea: 400mg once as a single dose. PID: 400mg every 12 hours for 10–14 days. Uncomplicated cystitis due to E. coli or K. pneumoniae: 200mg every 12 hrs for 3 days. Other uncomplicated cystitis: 200mg every 12 hrs for 7 days. Complicated UTIs: 200mg every 12 hrs for 10 days. Prostatitis due to E. coli: 300mg every 12 hours for 6 weeks. Severe hepatic impairment: max 400mg/day. Renal impairment: CrCl 20–50mL/min: give normal dose (loading dose) and increase dosing interval to 24 hours. CrCl <20mL/min: give normal dose once (loading dose) then ½ normal dose and increase dosing interval to 24 hours.
<18yrs: not recommended.
Increased risk of tendinitis or tendon rupture esp. in patients >60yrs, or those with kidney, heart, or lung transplants. CNS disorders (e.g., cerebral arteriosclerosis, epilepsy) that increase seizure risk. Discontinue if CNS effects, photosensitization, allergic reactions, peripheral neuropathy, or tendon pain, inflammation or rupture occurs. History of QT prolongation or proarrhythmic conditions (eg, hypokalemia, bradycardia, recent MI). May mask symptoms of syphilis; test for syphilis before treating gonorrhea then follow-up after 3 months. Maintain adequate hydration. Avoid excessive sun or UV light. Monitor blood, renal, and hepatic function in prolonged use. Renal or severe hepatic impairment. Pregnancy (Cat.C), nursing mothers: not recommended.
Avoid drugs that prolong QTc interval (eg, Class IA or Class III antiarrhythmics, erythromycin, antipsychotics, tricyclics). Separate dosing of magnesium- or aluminum-containing antacids and didanosine, sucralafate, iron, zinc, other metal cations (separate dosing by 2hrs). Increased risk of seizures with NSAIDs. May potentiate cyclosporine, theophylline, warfarin; monitor. May potentiate insulin, oral hypoglycemics (discontinue ofloxacin if hypoglycemia occurs). Increased risk of tendinitis and tendon rupture with corticosteroids. Monitor drugs metabolized by CYP450.
GI upset, dizziness, rash, pruritus, dysgeusia; CNS stimulation (eg, convulsions, nervousness, anxiety), hypersensitivity reactions, phototoxicity, tendinitis/rupture; rarely: peripheral neuropathy.
Formerly known under the brand name Floxin.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|